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Abstract
In order to develop transgenic animal models that selectively overexpress various AL peptides, we have developed a novel
expression system that selectively expresses AL40 or AL42 in the secretory pathway. This system utilizes fusion constructs in
which the sequence encoding the 23-amino-acid ABri peptide at the carboxyl terminus of the 266-amino-acid type 2
transmembrane protein BRI is replaced with a sequence encoding either AL40 or AL42. Constitutive processing of the
resultant BRI-AL fusion proteins in transfected cells results in high-level expression and secretion of the encoded AL peptide.
Significantly, expression of AL42 from the BRI^AL42 construct resulted in no increase in secreted AL40, suggesting that the
majority of AL42 is not trimmed by carboxypeptidase to AL40 in the secretory pathway. ß 2001 Elsevier Science B.V. All
rights reserved.
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1. Introduction
A great deal of genetic, biochemical and patholog-
ical evidence indicates that aggregation of amyloid L
protein (AL) plays a causative role in the develop-
ment of Alzheimer’s disease (AD) (reviewed in [1].
Based on this evidence, a number of AD transgenic
mouse models have been developed that deposit AL
in the central nervous system (reviewed in [2]). These
current models primarily rely on overexpression of
familial AD linked mutant amyloid L protein precur-
sor (APP) to generate su⁄cient levels of AL to drive
age-dependent aggregation and deposition. While
these models are extremely valuable tools to study
AL deposition and APP processing, the high levels
of mutant APP overexpression needed to achieve
amyloid deposition may confound interpretations of
pathological and behavioral studies. Not only could
mutant APP overexpression arti¢cially contribute to
some of the pathological and behavioral changes that
have been described, it is also possible that overex-
pression of APP and subsequent production of the
potentially neuroprotective sAPP derivatives may
paradoxically prevent these models from fully reca-
pitulating some features of human AD pathology
(e.g., readily appreciable neuronal loss).
0925-4439 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 9 2 5 - 4 4 3 9 ( 0 1 ) 0 0 0 5 4 - 0
* Corresponding author. Fax: +1-904-953-7370.
E-mail address: tgolde@mayo.edu (T.E. Golde).
1 Present address: Department of Human Genetics, Mount
Sinai School of Medicine, 1425 Madison Avenue, Box 1498, New
York, NY 10029, USA.
BBADIS 62042 13-7-01
Biochimica et Biophysica Acta 1537 (2001) 58^62
www.bba-direct.com
An obvious way to overexpress AL in the absence
of APP overexpression is to create minigenes encod-
ing the AL peptide itself or the AL peptide fused to
the APP leader peptide. Our experience with these
types of constructs is that they do not produce
high levels of AL and that only trace amounts of
AL get secreted from cultured cells transfected with
these AL minigene constructs (T.E. Golde, unpub-
lished observation). Similar results are reported in
the literature. In one case, transfection of an AL1^
43 minigene containing the APP signal peptide re-
sulted in AL1^43 expression primarily in the nucleus
and cytoplasm with only a small amount of intact
AL secreted [3]. In another case another AL minigene
was used to drive expression of AL1^42 in a trans-
genic mice. Although there was evidence for neuro-
nal cell death and evidence for immunohistochemical
staining of AL epitopes in some neurons, these mice
did not develop overt AD pathology [4]. Although
the neuronal death phenotype in these mice is intri-
guing, no follow up reports have been forthcoming,
and expression of AL has not been documented by
any other method than immunohistochemistry.
To develop a system whereby individual AL pep-
tides could be e⁄ciently expressed and secreted in the
absence of overexpression of the APP, we have cre-
ated genetic constructs that express fusion proteins
between the BRI protein, involved in amyloid depo-
sition in familial British dementia [5], and AL (see
Fig. 1). The expression of AL from these BRI^AL
fusion proteins was then examined in cell culture
systems.
2. Materials and methods
Polymerase chain reaction (PCR) primers were de-
signed to generate a 991 bp fragment of the BRI gene
[5], using human brain library cDNA as template.
The forward primer, 5P-TTC CCT CGA GTC TCA
GCC GCC CGG AGC-3P, and the reverse primer,
5P-ACT GCT CGA GAT GTA AAG GGT GGG
GTT ATG-3P, included the recognition sequence
for the restriction enzyme XhoI in their 5P sequence.
The ampli¢ed product was then digested with XhoI
to create a tagged fragment suitable for cloning into
pBS (KS3). The construct sequence was con¢rmed
by direct sequencing on an ABI 377 automated se-
quencer using Big Dye chemistry and Sequence Nav-
igator software (Perkin Elmer). This construct was
Table 1
ELISA analysis of cells transfected with BRI^AL fusion constructs
Cell line/DNA Transfectionb AL40 (pM)c AL42 (pM)d %AL40 %AL42
293T/pAG3a Transient 11 þ 3 0 100 0
293T/pAG3 BRI^AL40 Transient 145 þ 8 0 100 0
293T/pAG3 BRI^AL42 Transient 8 þ 2 161 þ 13 5 95
C17-2/pAG3 Transient 8 þ 1 2 þ 1 80 20
C17-2/pAG3 BRI^AL40 Transient 383 þ 26 2 þ 1 99 1
C17-2/pAG3 BRI^AL42 Transient 12 þ 3 475 þ 64 2 98
H4/pAg3 Stable 31 þ 5 4 þ 1 89 11
H4/pCDNA3APP695 Stable 694 þ 38 94 þ 3 88 12
H4/pAG3BRI^AL40 Stable 18735 þ 177 173 þ 28 99 1
H4/pAG3BRI^AL42 Stable 629 þ 9 28059 þ 159 2 98
(2b7) CHO/pAG3APP695wt Stable 3421 þ 420 392 þ 28 90 10
CHO/pAG3APP695NL,I,his Stable 12861 þ 1809 2902 þ 395 81 19
aThe pAG3 vector has been previously described [6].
bTransient transfections were performed in triplicate in 6-well plates using Fugene 6 (Roche). Stable lines were transfected with Fu-
gene 6 and selected with either hygromycin (pAG3) or G418 (pCDNA3). Each stable line was derived from a single colony that was
selected based on high-level expression.
cAL40 was assayed using a 3160/BA27 ELISA.
dAL42 was assayed using a 3160/BC05 ELISA. The small amount of AL1^40 detected above background cells transfected with BRI^
AL42 is likely due to the fact that the AL40 ‘speci¢c’ BA-27 antibody will detect AL1^42 at low e⁄ciencies (V1%) [14,15]. A similar
cross-reactivity is likely to account for the small amount of AL42 detected in the BRI^AL40 transfects. In all cases, media samples
were conditioned for 16 h.
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used for the template in the subsequent PCR reac-
tions.
Subsequently, fusion constructs encoding the ¢rst
243 amino acids of BRI followed by either AL40
(BRI^AL40) or AL42 (BRI^AL42) were generated
by PCR ampli¢cation. The amino terminal portion
encoding BRI was ampli¢ed using the wild-type BRI
cDNA as template and the primers BRIFOR (5P-
ATTTTTAAGCTTCTCGAGAGGCTGCAATCG-
CAGCGGGAG-3P) and BRIREV (5P-GTCGGA-
ATTCTGCATCACGTTTCTGAATACCTTTAAT-
AGTTTC-3P). cDNAs encoding AL40 and AL42
were ampli¢ed using APP 695 wild-type cDNA as
template and the primer ALFOR (5P-TGGA-
GATCTGATGCAGAATTCCGACATGACTC-3P),
and AL40REV (5P-TAAAAGGATCCCTAGACAA-
CACCGCCCACCATGAG-3P) and AL42REV (5P-
TAAAAGGATCCCTACGCTATGACAACACCG-
CCCACCATGAG-3P). The resultant BRI encoding
cDNA was digested with HindIII and EcoRI while
the AL encoding cDNAs were digested with EcoRI
and BamHI. The fragments were ligated into the ex-
pression vector pAG3 using a three-way ligation that
resulted in an in frame fusion of the BRI and AL
sequences. Sequences were con¢rmed by automated
DNA sequencing. These PCRs were performed using
the High ¢delity PCR kit from Roche. Transfection
of cells, AL enzyme-linked immunosorbent assays
(ELISAs), and immunoprecipitation^mass spectrom-
etry (IP/MS) were carried out as previously described
[6]. Western blotting was carried out as described
previously using BAN50, BC05 and BA27 antibodies
at 1:1000 [7]. An anti-peptide antibody, EN3, raised
in rabbit, created to the sequence YKLQRRETIK-
GIQ (corresponding to amino acids 229^241 of BRI)
was also used at a dilution of 1:1000.
3. Results and discussion
To determine whether the BRI^AL fusion proteins
produce AL, we initially analyzed conditioned media
from human embryonic kidney cells (293T) and
mouse CNS progenitor cells (C17-2) [8] transiently
transfected with BRI^AL40 and BRI^AL42 using
end-speci¢c AL ELISAs. These data indicated that
AL40 was selectively produced from the BRI^AL40
construct and AL42 was selectively produced from
the BRI^AL42 construct (see Table 1). To further
investigate the expression of AL from these con-
structs we generated stable H4 neuroglioma. As
with the transient transfections, each BRI fusion
Fig. 1. BRI^AL fusion proteins. (A) Schematic of wild-type BRI, mutant BRI, BRI^AL40 and BRI^AL42 fusion proteins. The amino
acids immediately surrounding the furin cleavage site (indicated by a slash) in the BRI and BRI mutant are indicated above BRI wild
type. The amino acids forming the cleavage site in the AL fusions are indicated below BRI^AL42. Note that the substitution at P1P in
the BRI fusions is quite conservative. (B) Schematic of furin cleavage of BRI. BRI is cleaved by furin (and possibly other furin like
proteases) to cleave the ABri peptide from the BRI protein. Similar processing in the BRI^AL fusions should release authentic AL
peptides.
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construct resulted in selective overexpression of the
appropriate AL peptide (Table 1), with over 98% of
the AL generated ending with the designed amino
acid. We also compared the production of AL from
the BRI fusion constructs to that generated by 2b7
cells and CHO-APP695NL,I,his cells. The 2b7 clonal
CHO line secretes the highest levels of AL of any
wild-type APP transfected line generated in our lab-
oratory, and the CHOAPP695NL,I,his cells express
the highest level of AL from any stable cell line we
have ever generated, presumably because the NL mu-
tation increases AL40 and AL42 production whereas
the V717I (I) increases the percent AL42. Signi¢-
cantly, the speci¢c levels of AL40 or AL42 were
much higher using the BRI fusion methodology. To
obtain ¢nal conformation of the selectivity of AL
secretion form this system, IP/MS analysis of the
media was performed. As shown in Fig. 2A,B, the
mass spectra demonstrate that each construct results
in the selective overexpression of the appropriate full
length AL peptide (AL1^40 from BRI^AL40 and
AL1^42 from BRI^AL42) with negligible increase in
any other peptide peaks. Western blot analysis of the
H4 stable lines expressing the BRI^AL fusion pro-
teins with antibodies to the amino terminus of AL,
AL40, AL42, and BRI indicates that fusion proteins
containing the expected epitopes and of the appro-
priate size (V36 kDa) are produced by expression of
the BRI^AL constructs (Fig. 2C).
Familial British dementia is an autosomal domi-
nant genetic disorder, characterized by the deposition
of the 34-amino-acid ABri peptide, as amyloid in
non-neuritic plaques and cerebral vessels. Cloning
of the gene encoding the ABri peptide revealed that
it is derived from the carboxyl terminus of a type 2
transmembrane protein referred to as BRI [5]. In the
mutant BRI protein, a T-A transversion in the stop
codon results in an 11-amino-acid extension of the
coding sequence. The 266-amino-acid wild-type and
277-amino-acid mutant BRI precursor proteins are
C
Fig. 2. Analysis of BRI^AL fusion proteins. (A) IP/MS analysis
of conditioned media from a stable H4 cell line expressing
BRI^AL40. AL species are indicated above the peaks and the
mass is enclosed in parentheses. Note that no AL42 is detected
by IP/MS and that only minor amounts of smaller AL peptides
(AL1^32, AL1^34, AL1^37 and AL1^39) are detected. The
shoulder on the 1^40 peak corresponds to the AL1^40 peptide
complexed with a sodium ion. The levels determined by ELISA
analysis of this media are shown in Table 1 (H4/pAG3BRI^
AL40). (B) IP/MS analysis of conditioned media from a stable
H4 cell line expressing BRI^AL42 reveals that AL42 represents
the vast majority of AL produced by this construct. AL levels
determined by ELISA analysis of this media are shown in Ta-
ble 1 (H4/pAG3BRI^AL42). In vector transfected H4 cells, only
a small peak corresponding to AL1^37 is detected by IP/MS
(data not shown). (C) Western blot analysis of BRI^AL fusion
constructs with BAN50, an antibody that recognizes the amino
terminus of AL. Additional Western blot analyses with anti-
body EN3 to the BRI sequence showed identical results to the
BAN50 blot (data not shown). Blotting with the antibody
BC05 that recognizes AL42 and BA27 that recognizes AL40
stained only the appropriate BRI fusion proteins (data not
shown).
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cleaved by furin (and possibly other furin-like pro-
teases) to release both wild-type (23 aa) and mutant
Abri (34 aa), respectively (Fig. 1) [9]. As the speci¢c-
ity of furin-like proteases is primarily in the P1^P2
residues [10,11], we speculated that expression of
BRI fusion proteins in which the ABri sequence
was replaced by AL sequence would result in cleav-
age of the heterologous peptide and subsequent se-
cretion of AL. As predicted, the results described
herein indicate that BRI^AL fusion protein expres-
sion results in the selective secretion of the encoded
AL peptide. Thus, we have proven the utility of the
BRI fusion system for expressing AL in the secretory
system of mammalian cells. Given the aforemen-
tioned speci¢city of the furin cleavage lies in the res-
idues amino terminal to the cleavage site, it is likely
that a variety of small peptide sequences can be fused
to BRI and subsequently released by furin endopro-
teolysis. Moreover, this system may prove useful for
expression of AL in non-mammalian animal models
such as Drosophila and Caenorhabditis elegans. These
models do not e⁄ciently process full-length APP into
AL, but are known to process many proteins con-
taining dibasic furin cleavage sites [12] making it
likely that furin cleavage of BRI^AL fusions result
in a high level of AL production in these model or-
ganisms.
This study also suggest that AL42 produced in the
secretory pathway of several mammalian cell types is
not trimmed by carboxypeptidases to generate small-
er AL peptides. This result further supports the no-
tion that AL40 and AL42 are generated solely by
endoproteolysis of APP. Because we do not know
whether the BRI^AL fusion proteins are produced
in exactly the same secretory pathways that produce
AL from the APP, we cannot completely exclude the
possibility that carboxypeptidase trimming of AL42
occurs in vivo. Nevertheless, both furin cleavage of
other substrates and APP processing to AL have
been shown to occur in the late Golgi; therefore, it
is likely that AL production from APP and BRI^AL
fusion proteins, at least to some extent, occur in
overlapping pathways.
The study of familial forms of AD has ¢rmly es-
tablishing a pathogenic role for ‘long’ AL species
ending at AL42 [13]. Yet, multiple AL peptides
with varying carboxyl and amino termini are pro-
duced and deposited in the AD brain. Unfortunately,
little is known about the potential role that various
truncated AL species play in the development of AD;
the ability to selectively express speci¢c AL peptides
from BRI^AL fusion constructs may enable the path-
ogenicity of individual AL peptide to be determined
in animal models.
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